Stem Cell Therapeutics Corp. has received Orphan Drug designation from the FDA for the use of tigecycline in the treatment of acute myeloid leukemia (AML). The company’s program is based on Dr. Aaron Schimmer’s published findings that tigecycline, an FDA-approved antibiotic, selectively targets leukemia cells and leukemic stem cells by inhibiting mitochondrial protein synthesis and thus shutting down the cells’ energy supply. A Phase I Canadian and U.S. multicenter dose-escala...